Pfizer’s Pegfilgrastim Biosimilar ‘Has Launched’ In The US

FDA Approval In June 2020 Hung Up By IP Barriers

F1
Pfizer has entered the race for market share in the mult-billion-dollar US pegfilgrastim market • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products